Clinical Trial Update: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of TBio-4101 (TIL) with pembrolizumab in advanced solid tumors has been terminated; the trial includes multiple indications such as breast cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Cutaneous Melanoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Uveal Melanoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TBio-4101 (TIL) (Tumor-infiltrating lymphocytes)

Snippet

Sponsor: Turnstone Biologics, Corp. | Conditions: Breast Cancer, Colorectal Cancer | Phase 1 | Status: TERMINATED